Treating BRAF V600E-mutant NSCLC with dabrafenib and trametinib 

Bruce Johnson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses follow-up data from a Phase II trial (NCT01336634) assessing dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After a 5 year follow-up, the median overall survival (OS) was the 19% and 22% in the pre-treated and treatment-naïve cohorts respectively and the median progression-free survival (PFS) was 10 months for both cohorts. Further analysis demonstrated inferior survival rates in patients with mutations other than V600E including MTOR, KRAS and other BRAF mutations. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).